Expression of and as potential biomarkers in chronic myeloid leukemia patients in Brazil.

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm in which all the patients has the translocation () that generates de BCR::ABL1 tyrosine kinase. Despite this disease possessing a good biomarker ( transcripts level) for diagnosis and prognosis, many studies has been performed to investigate other molecules, such as the long noncoding RNAs (lncRNAs) and mRNAs, as potential biomarkers with the aim of predicting a change in levels and as an associated biomarker. A RNAseq was performed comparing 6 CML patients with high expression with 6 healthy control individuals, comprising the investigation cohort to investigate these molecules. To validate the results obtained by RNAseq, samples of 87 CML patients and 42 healthy controls were used in the validation cohort by RT-qPCR assays. The results showed lower expression of and in CML patients. The expression is inversely associated with expression in imatinib-treated CML patients, and to showing that CML patients with high expression showed reduced expression.